C-Reactive Protein Testing Global Market Report 2024

C-reactive protein (CRP) testing is a diagnostic procedure that assesses the concentration of CRP in the bloodstream, a protein produced by the liver in response to inflammation. In cases of injury or infection, the body initiates inflammation as a protective mechanism. CRP testing is primarily employed to identify inflammation resulting from infections.

The primary assay methods utilized in the CRP testing market include enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and immunoturbidimetric assays. ELISA, for instance, is a technique employed to quantitatively measure human CRP levels in serum, aiding in the monitoring of conditions such as rheumatic fever and inflammatory processes. ELISA serves as a biological assay focusing on the measurement of antibodies, antigens, proteins, and glycoproteins. CRP testing is widely applied in clinical settings, hospitals, and diagnostic laboratories, contributing to the diagnosis and monitoring of various conditions such as diabetes, rheumatoid arthritis, cardiovascular diseases, inflammatory bowel disease, cancer, and others.

The c-reactive protein testing market research report is one of a series of new reports that provides c-reactive protein testing market statistics, including c-reactive protein testing industry global market size, regional shares, competitors with an c-reactive protein testing market share, detailed c-reactive protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. This c-reactive protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The c-reactive protein testing market size has grown steadily in recent years. It will grow from $3.43 billion in 2023 to $3.55 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. During the historical period, the growth in the C-reactive protein testing market can be attributed to the heightened prevalence of inflammatory diseases, the need for cardiovascular risk assessment, a growing aging population, expanded healthcare infrastructure, and the implementation of healthcare screening programs.

The c-reactive protein testing market size is expected to see steady growth in the next few years. It will grow to $4.16 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. In the forecast period, the growth of the C-reactive protein testing market can be attributed to the escalating rates of obesity, the emphasis on personalized medicine and biomarkers, the increasing adoption of telehealth and remote monitoring, the demand for early disease detection, and the prevalence of lifestyle-related inflammation. Major trends during this period include advancements in diagnostic testing, the integration of wearable health technology, the introduction of technological solutions, strategic collaborations, and the implementation of Industry 4.0 practices.

The escalating incidence of cardiovascular diseases (CVD) is poised to drive the expansion of the c-reactive protein testing market. Cardiovascular diseases encompass a spectrum of heart-related conditions, including diseased vessels, structural issues, and blood clots. Various factors contribute to the risk of developing CVD, including behavioral risks such as imbalanced eating, lack of physical activity, smoking, and alcohol use, leading to the accumulation of fatty deposits within arteries (atherosclerosis). This scenario increases the risk of blood clots, elevated blood pressure, glucose, blood lipids, weight gain, and obesity. Given the growing prevalence of cardiovascular diseases, the demand for c-reactive protein testing is on the rise, as it proves effective in diagnosing or predicting the likelihood of cardiovascular problems, comparable to cholesterol levels. According to the World Health Organization (WHO), cardiovascular diseases are the primary cause of global mortality, with 17.9 million deaths annually, constituting 32% of all worldwide deaths. Hence, the surging instances of cardiovascular diseases are expected to propel the c-reactive protein testing market's growth.

The increasing number of clinical trials is anticipated to further boost the c-reactive protein testing market. Clinical trials play a crucial role in assessing the safety, efficacy, and potential benefits of medical interventions, including diagnostic procedures like c-reactive protein testing. These trials are instrumental in evaluating the accuracy and efficacy of CRP testing in diagnosing cardiovascular diseases and predicting the risk of heart-related conditions. As of May 2023, there are 452,604 clinical studies registered on ClinicalTrials.gov, with 64,838 actively seeking participants, marking a notable increase from early 2021. This rise in clinical trials underscores the growing importance of c-reactive protein testing, contributing to the market's expansion.

A noteworthy trend in the c-reactive protein testing market is the technological advancement in measuring devices. Key players in the market are prioritizing technological innovation to strengthen their market positions. These companies are integrating next-generation c-reactive testing technologies into their methods, providing advanced solutions with benefits like maximum output and multiple usages. For example, Aidian, a Finnish-based diagnostic tests and solutions company, introduced the QuikRead go wrCRP & wrCRP+Hb kits in February 2022. This kit delivers two results, a wide range of CRP and Hb, from a single sample with one analysis. The wide-range CRP test allows for CRP readings that assess conditions like neonatal sepsis, predict disease severity in COPD, and aid in cardiovascular risk assessment. This technological advancement reflects a commitment to offering efficient and comprehensive c-reactive protein testing solutions.

Key players in the c-reactive protein testing market are prioritizing innovation by introducing new technological treatments, such as the C-Reactive Protein antigen test, to enhance their market standing and profitability. The C-Reactive Protein (CRP) antigen test is a blood test designed to measure the body's level of C-Reactive Protein, a protein produced by the liver in response to inflammation. LumiraDx Healthcare Pvt Ltd., an India-based medical technology company, launched the C-Reactive Protein antigen test in November 2022. This microfluidic immunoassay offers a quick and simple way to measure CRP levels in whole blood, providing an automated in vitro diagnostic test for healthcare professionals to use in close proximity to patients.

In October 2021, Abcam, a UK-based company specializing in protein research tools, acquired BioVision Inc. for $340 million. This strategic move aimed to bolster Abcam's immunoassay capacity in Eugene, OR, by expanding its portfolio of kits and assays. The acquisition of BioVision Inc., a US-based innovator and distributor of life science research tools, including CRP ELISA kits, positions Abcam to accelerate strategy execution, focus on in-house innovation, and develop products in the complementary biochemical and cell-based assay markets. This highlights a commitment to advancing capabilities and product offerings in the c-reactive protein testing market.

Major companies operating in the c-reactive protein testing market include Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Abaxis Inc., Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., ProciseDx LLC, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Johnson & Johnson Clinical Diagnostics, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech PLC, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Corgenix Medical Corporation, Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation

North America was the largest region in the c-reactive protein testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the c-reactive protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.